BACKGROUND: Drugs that kill or inhibit Plasmodium gametocytes in the human host could potentially synergize the impact of other chemotherapeutic interventions by blocking transmission. To develop such agents, reliable methods are needed to study the in vitro activity of compounds against gametocytes. This study describes a novel assay for characterizing the activity of anti-malarial drugs against the later stages of Plasmodium falciparum gametocyte development using real-time PCR (qPCR). METHODS: Genes previously reported to be transcribed at the different sexual stages of the gametocytogenesis were selected for study and their mRNA expression was measured in a gametocytogenesis course by qPCR. Genes mainly expressed in the later stages of gametocyte development were used as a surrogate measurement of drug activity. To distinguish between cidal and static drug effects, two different experiments were performed in parallel, one with constant drug pressure throughout the experiment (144 h), and another in which the gametocyte cultures were exposed to the compound for only 48 h. RESULTS: Four P. falciparum genes coding for proteins Pf77, ROM3, Pfs25, and Pfg377 with transcription specific for late-stage gametocyte development were identified. The in vitro anti-malarial activity of compounds against such gametocytes was assessed by measuring mRNA levels of these genes using qPCR. The assay was validated against standard anti-malarial drugs (epoxomicin, dihydroartemisinin, chloroquine, thiostrepton, and methylene blue) and compounds from the GSK compound library with known anti-gametocyte activity. CONCLUSIONS: This study describes a novel assay for characterizing the activity of anti-malarial drugs against the later stages of P. falciparum gametocyte development using qPCR in genetically unmodified parasites. The method described is a reliable and user-friendly technique with a medium throughput that could be easily implemented in any laboratory.
BACKGROUND: Drugs that kill or inhibit Plasmodium gametocytes in the human host could potentially synergize the impact of other chemotherapeutic interventions by blocking transmission. To develop such agents, reliable methods are needed to study the in vitro activity of compounds against gametocytes. This study describes a novel assay for characterizing the activity of anti-malarial drugs against the later stages of Plasmodium falciparum gametocyte development using real-time PCR (qPCR). METHODS: Genes previously reported to be transcribed at the different sexual stages of the gametocytogenesis were selected for study and their mRNA expression was measured in a gametocytogenesis course by qPCR. Genes mainly expressed in the later stages of gametocyte development were used as a surrogate measurement of drug activity. To distinguish between cidal and static drug effects, two different experiments were performed in parallel, one with constant drug pressure throughout the experiment (144 h), and another in which the gametocyte cultures were exposed to the compound for only 48 h. RESULTS: Four P. falciparum genes coding for proteins Pf77, ROM3, Pfs25, and Pfg377 with transcription specific for late-stage gametocyte development were identified. The in vitro anti-malarial activity of compounds against such gametocytes was assessed by measuring mRNA levels of these genes using qPCR. The assay was validated against standard anti-malarial drugs (epoxomicin, dihydroartemisinin, chloroquine, thiostrepton, and methylene blue) and compounds from the GSK compound library with known anti-gametocyte activity. CONCLUSIONS: This study describes a novel assay for characterizing the activity of anti-malarial drugs against the later stages of P. falciparum gametocyte development using qPCR in genetically unmodified parasites. The method described is a reliable and user-friendly technique with a medium throughput that could be easily implemented in any laboratory.
Entities:
Keywords:
Gametocyte; Gene expression; Plasmodium falciparum; Real time PCR; Transmission; mRNA; qPCR
Authors: Christopher L Peatey; Tina S Skinner-Adams; Matthew W A Dixon; James S McCarthy; Donald L Gardiner; Katharine R Trenholme Journal: J Infect Dis Date: 2009-11-15 Impact factor: 5.226
Authors: Jason A Young; Quinton L Fivelman; Peter L Blair; Patricia de la Vega; Karine G Le Roch; Yingyao Zhou; Daniel J Carucci; David A Baker; Elizabeth A Winzeler Journal: Mol Biochem Parasitol Date: 2005-09 Impact factor: 1.759
Authors: Celia Miguel-Blanco; Joël Lelièvre; Michael J Delves; Ana I Bardera; Jesús L Presa; María José López-Barragán; Andrea Ruecker; Sara Marques; Robert E Sinden; Esperanza Herreros Journal: Antimicrob Agents Chemother Date: 2015-03-23 Impact factor: 5.191
Authors: Pedro L Alonso; Graham Brown; Myriam Arevalo-Herrera; Fred Binka; Chetan Chitnis; Frank Collins; Ogobara K Doumbo; Brian Greenwood; B Fenton Hall; Myron M Levine; Kamini Mendis; Robert D Newman; Christopher V Plowe; Mario Henry Rodríguez; Robert Sinden; Laurence Slutsker; Marcel Tanner Journal: PLoS Med Date: 2011-01-25 Impact factor: 11.069